Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-...(ll will also beavailable by phone for 24...),Health

About Diabetes

Diabetes affects more than 20 million people in the U.S. and an estimated 246 million adults worldwide(1,2). Approximately 90-95 percent of those affected have type 2 diabetes. Diabetes is the fifth leading cause of death by disease in the United States and costs approximately $132 billion per year in direct and indirect medical expenses(3). Approximately 90 percent of people with diabetes are obese or overweight(4).

According to the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of diabetes patients do not achieve target blood sugar levels with their current treatment regimen(5). Nearly half of newly treated patients with diabetes do not adhere to their treatment regimen(6).

About BYETTA(R) (exenatide) injection

BYETTA is the first in a class of drugs for the treatment of type 2 diabetes called incretin mimetics. BYETTA exhibits many of the same effects as the human incretin hormone glucagon-like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain. BYETTA is approved by the FDA for use by people with type 2 diabetes who are unsuccessful at controlling their blood sugar levels. BYETTA is add-on therapy for people currently using metformin, a sulfonylurea, or a thiazolidinedione. BYETTA provides sustained A1C control, low incidence of hypoglycemia when used with metformin or a thiazolidinedione, and progressive weight loss. For full prescribing information, visit http://www.BYETTA.com.

Important Safety Information for BYETTA

BYETTA improves blood sugar control in adults with type 2 di
'/>"/>